Menu Search
Equities

Vaxcyte Inc

5VA:DUS

Vaxcyte Inc

Actions
  • Price (EUR)85.50
  • Today's Change-1.00 / -1.16%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:32 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

  • Revenue in USD (TTM)0.00
  • Net income in USD-507.65m
  • Incorporated2013
  • Employees254.00
  • Location
    Vaxcyte Inc825 INDUSTRIAL ROAD, STE. 300SAN CARLOS 94070United StatesUSA
  • Phone+1 (650) 837-0111
  • Fax+1 (302) 655-5049
  • Websitehttps://vaxcyte.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.